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Abstract
Dysregulated anger is often present in the emotional (i.e., anxiety, mood, and related) disorders, 
however it is rarely targeted in treatment. Transdiagnostic treatments, which focus on processes 
that contribute to dysregulated emotions across the range of psychopathology, might represent an 
efficient way to treat this anger. Using a subset of data from a recently completed equivalency trial 
comparing the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) to 
single diagnosis protocols (SDPs) for specific disorders, this study began exploring whether the 
UP led to great reductions in anger compared to the SDPs. Results indicated that there was a 
small, non-significant, decrease in anger in the UP condition, whereas there was a moderate, non-
significant increase in anger in the SDP condition. At post treatment, UP patients had significantly 
lower anger scores than patients who received a SDP. These preliminary results suggest that 
transdiagnostic treatments may be well poised to target dyregulated anger in the context of 
emotional disorders.
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In recent years, transdiagnostic conceptualizations of psychopathology and treatment have 
gained prominence (e.g., Brown & Barlow, 2009; Sauer-Zavala et al., 2017), representing a 
shift from categorical classification systems such as the Diagnostic and Statistical Manual of 
Mental Disorders – 5th edition (DSM-5; American Psychiatric Association, 2013). 
Specifically, transdiagnostic perspectives emphasize shared vulnerabilities that account for 
the development and maintenance of a variety of conditions. For example, the term 
“emotional disorder” is often used to describe a range of depressive, anxiety, and related 
disorders (e.g., trauma-related disorders, obsessive-compulsive disorder, and borderline 
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personality disorder; Sauer-Zavala & Barlow, 2014). A functional model of emotional 
disorders suggests that they are maintained by aversive reactions to the experience of 
frequent and intense emotions, including perceptions that such experiences are unacceptable 
and/or uncontrollable (neuroticism; Barlow et al., 2014; Cassiello-Robbins et al., in press). 
These aversive reactions, in turn, lead to efforts to escape the emotional experience through 
the use of avoidance strategies that reduce distress in the short-term but paradoxically 
maintain it in the long-term (Campbell-Sills & Barlow, 2007; Sauer-Zavala & Barlow, 
2014). This model has largely been applied to the experience of anxiety and depression, 
though may be relevant for a broader range of emotions.
Like all emotions, anger has an adaptive function; it can alert an individual to a potential 
threat (e.g., being treated unfairly) or blocked goal, and motivate defensive, protective, or 
goal-directed behavior (Harmon-Jones & Harmon-Jones, 2016). Also, like other emotions, 
anger becomes dysregulated when it ceases to motivate behavior that serves an individual’s 
long-term interests, instead prompting actions that are interfering and distressing. From a 
theoretical standpoint, this dysregulated anger fits into the model of emotional disorders 
(Sauer-Zavala & Barlow, 2014). That is, an individual can experience anger, have an 
aversive reaction to it, and subsequently engage in attempts to escape or avoid this emotion. 
These attempts may result in a variety of maladaptive methods of anger expression including 
externalizing behavior (e.g., yelling, breaking objects) or internalizing behavior (e.g., 
suppression) that interfere with the patient’s daily life. For example, research suggests that 
efforts to suppress an unwanted thought can lead to its continued persistence as well as 
increased negative affectivity (Davies & Clark, 1998). Thus the suppression of unwanted, 
angry, thoughts may actually lead to increased anger, even though it reduces the patient’s 
anger in the short-term.
Despite these similarities, dysregulated anger is often under recognized and under-explored 
in the context of emotional disorders (for a review see Cassiello-Robbins & Barlow, 2016). 
This is especially troubling given that the presence of such anger in these disorders is 
associated with a number of notable consequences including greater disorder severity and 
higher levels of comorbidity (e.g., Cassiello-Robbins & Barlow, 2016). In the context of 
treatment, elevated anger in emotional disorders is associated with lower engagement, higher 
likelihood of attrition (e.g., Cassiello-Robbins et al., 2015; Wnuck et al., 2013) and a poorer 
treatment outcome (Erwin et al., 2003; Fava et al., 1991; Rosen et al., 2001).
These findings highlight the importance of understanding and effectively treating 
dysregulated anger in this context. Given that it fits theoretically into the model of emotional 
disorders, treatment principles that intervene on this model might also be effective for 
targeting dysregulated anger. The Unified Protocol for the Transdiagnostic Treatment of 
Emotional Disorders (UP; Barlow, Farchione et al., 2011; 2018) has begun to gather 
evidence as an efficient intervention for a range of co-occurring emotional disorders. In 
contrast to single diagnosis protocols (SDPs) that are designed to target individual disorders 
(i.e., panic disorder, social anxiety, etc.), the UP purports to target the core mechanism 
believed to underlie these disorders – aversive, avoidant reactions to emotions. The UP 
targets this process by educating patients about the adaptive nature of emotions in order to 
cultivate a willing and accepting attitude towards experiencing them. In this cognitive-
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behavioral therapy (CBT) protocol, patients are taught strategies to modify faulty emotion 
regulation, including mindful awareness of emotions, cognitive flexibility, and reduction in 
the use of safety behaviors. They also engage in emotion exposures. Throughout, all 
treatment strategies are used to emphasize the adaptive nature of emotions and encourage 
patients to approach and experience their emotions in order to decrease reliance on 
avoidance-based emotion regulation strategies. The implementation of these skills is thought 
to facilitate the extinction of distress in response to the experience of strong emotions.
The UP has shown promising results in the treatment of anxiety disorders (panic disorder, 
generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder; 
Ellard, et al., 2010; Farchione et al., 2012), as well as major depressive disorder (Boswell et 
al., 2014; Ellard et al., 2010; Farchione et al., 2012), bipolar disorder (Ellard, et al., 2012), 
post-traumatic stress disorder (Gallagher, in press), and borderline personality disorder 
(BPD; Lopez et al., 2015; Sauer-Zavala et al., 2016). Notably, anger is a diagnostic criterion 
for BPD and the success of the UP in this context might suggest that its treatment principles 
can be applied to this emotion. However, in prior studies of the UP for BPD, outcomes 
related to anger were not specifically examined. Recently, a large randomized controlled 
trial was conducted examining whether the UP is at least as efficacious at treating 
heterogeneous anxiety disorders (panic disorder with or without agoraphobia, generalized 
anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder) as evidence-
based gold standard single diagnosis protocols (SDPs). In this study, patients were randomly 
assigned to receive the UP, SDP, or waitlist control condition. The results indicated that the 
efficacy of the UP for anxiety disorders was equivalent to the SDPs with less attrition 
(Barlow et al., 2017). This accumulating evidence supports the idea that the UP can 
effectively treat dysregulated fear, anxiety, and depression; however, its effect on other 
dysregulated emotions has yet to be examined.
Thus, the current study sought to explore patterns of change in anger during treatment by 
conducting an initial evaluation of the effects of CBT in general and the UP specifically on 
anger. The aims of the current study were 1) to replicate the current literature regarding the 
associations of dysregulated anger with greater symptom severity (using patients in all study 
conditions) and lower likelihood of responding to treatment (for patients who received 
treatment), 2) to examine whether anger changed in cognitive-behavioral therapy for anxiety 
disorders within each treatment condition (UP and SDP conditions), 3) to examine whether 
individuals receiving the transdiagnostic treatment (UP) evidenced greater reductions in 
anger than those receiving SDP treatment. We predicted that anger would be associated with 
greater symptom severity and lower likelihood of responding to treatment, that CBT would 
be associated with reductions in anger, and that the UP would be associated with larger 
reductions in anger than SDPs due to its broader focus on emotion regulation.
Method
Participants
Thirty-five patients were drawn from a larger (n = 223; Barlow et al., 2017) treatment trial 
conducted at the Boston University Center for Anxiety and Related Disorders (CARD). 
Participants were included in the present study if they completed all measures relevant to the 
Cassiello-Robbins et al. Page 3













proposed analyses. As the PANAS hostility subscale (see Measures) was a late addition to 
the larger trial, a smaller subset of eligible patients (35) completed this measure. 
Additionally, the following inclusion criteria were required for participation in the larger 
study and, by extension, the present study: principal (most interfering and distressing) 
diagnosis of panic disorder (PD), generalized anxiety disorder (GAD), obsessive-compulsive 
disorder (OCD), or social anxiety disorder (SOC), assessed using the Anxiety Disorders 
Interview Schedule (ADIS; Di Nardo et al., 1994); 18 years of age or older; fluent in 
English; and able to attend all treatment sessions and assessments. Stability on psychotropic 
medication for at least six weeks before enrolling in the study and willingness to refrain 
from making any medication changes during treatment was also required. Exclusion criteria 
were mostly conditions warranting immediate or simultaneous treatment that could interact 
with the study treatment in unknown ways (e.g., current diagnosis bipolar disorder, 
schizophrenia, schizoaffective disorder, or organic mental disorder, imminent suicide risk, 
recent history of substance abuse or dependence). Participants who attended eight or more 
CBT sessions within the past five years were also excluded.
The average age of patients included in the present study was 31.3 (SD = 11.0) and 
approximately half the sample was male (n = 18). The majority of the patients (n = 33) 
identified as Caucasian, one as Asian, and one as Black or African American. The most 
common principal diagnosis was PD (n = 18), followed by OCD (n = 16), and GAD (n = 1), 
with an average CSR representing “moderate” to “severe” impairment from this diagnosis 
(M = 5.77, SD = .81). Patients had an average of 3.17 comorbid diagnoses (SD = 2.07). The 
most common comorbid diagnoses were GAD (n = 14), SOC (n = 9), and post-traumatic 
stress disorder (n = 3). Of these 35 patients, 10 patients were in the waitlist condition, 11 
were in the SDP condition, and 14 were in the UP condition.
Measures
Anxiety Disorders Interview Schedule (ADIS; Brown & Barlow, 2014)—Patients 
were assessed for current DSM diagnoses using the ADIS, a semi-structured diagnostic 
clinical interview, by study evaluators blinded to condition allocation. Diagnoses are 
assigned a clinical severity rating (CSR) on a scale from 0 (no symptoms) to 8 (extremely 
severe symptoms), with a rating of 4 or above (definitely disturbing/disabling) passing the 
clinical threshold. All patients whose data were included in this study’s analyses were 
evaluated using DSM-5 criteria.
Overall Anxiety Severity and Impairment Scale (OASIS; Norman et al., 2006)—
The OASIS is a brief, 5-item questionnaire developed as a continuous measure of anxiety-
related symptom severity and impairment. Each item is rated on a 5-point scale and higher 
scores are indicative of greater severity and impairment. Psychometric studies have shown 
the OASIS to have excellent internal consistency and test-retest-reliability, as well as 
convergent and discriminant validity among outpatients (e.g., Campbell-Sills et al., 2009; 
Norman et al., 2013).
Overall Depression Severity and Impairment Scale (ODSIS; Bentley et al., 
2014)—The ODSIS is a brief, 5-item questionnaire developed as a continuous measure of 
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depressive-related symptom severity and impairment. Items are rated on a 5-point scale, with 
higher total scores indicating higher levels of depression. The ODSIS demonstrated 
excellent internal consistency and convergent and discriminant validity in its initial 
validation and was shown to discriminate between patients with and without a depressive 
disorder (Bentley et al., 2014).
The Positive and Negative Affective Schedule-Expanded Form, Hostility 
Subscale (PANAS-X; Watson & Clark, 1999)—The PANAS is a well-established 
measure of positive and negative affect, and inquired to what extent patients experienced 
various emotions in general. This time frame assesses the extent to which an emotion is a 
trait of an individual’s affect. The hostility subscale captures how much someone feels 
angry, hostile, irritable, scornful, disgusted, and loathing, and thus was used in this study as 
a measure of anger intensity. Of note, this subscale measures hostility as a normally 
distributed trait, and not a pathological condition. This subscale has demonstrated good 
psychometric properties in many prior studies, including internal consistency and stability 
over time (α = .85; e.g., Crawford & Henry, 2004; Watson et al., 1988). Given the 
preliminary nature of this study, and the need to minimize patient burden in a large clinical 
trial, this measure was chosen because it was the most parsimonious measure carrying strong 
psychometric support.
Eysenck Personality Questionnaire Revised – Short-Form (EPQR-S; Eysenck 
& Eysenck, 1975; Eysenck et al., 1985)—The EPQR-S is a 24-item questionnaire 
assessing temperament, namely, dimensions of extraversion, neuroticism, and psychoticism, 
as well as a lie scale. The EPQR-S has demonstrated good internal consistency, test-retest 
reliability, and concurrent validity (Francis, et al., 1992).
Procedures
The Boston University institutional review board approved all study procedures and written 
informed consent was obtained from patients prior to participation. The larger trial consisted 
of 16 sessions of an acute treatment phase (12 sessions for patients with a principal 
diagnosis of PD) or 16-week waitlist control (WLC), followed by a 6-month follow-up 
phase (in which WLC patients did not participate). The acute treatment phase was limited to 
a maximum of 21 weeks (16 weeks for PD). Patients were randomized by principal 
diagnosis with a 2:2:1 allocation ratio to UP, SDP, and WLC study conditions, respectively. 
The study coordinator was blind to these assignments until after each participant completed 
the diagnostic evaluation that determined final study eligibility.
Interventions
Unified Protocol for Transdiagnostic Treatment of Emotional Disorders—The 
UP was delivered in accordance with the published therapist guide (Barlow et al., 2011a) 
and client workbook (Barlow et al., 2011b). This treatment consists of five core treatment 
modules: mindful emotion awareness (Module 3), cognitive flexibility (Module 4), 
countering emotional behaviors (Module 5), understanding and confronting physical 
sensations (Module 6), and emotion exposures (Module 7). Patients also received two 
introductory modules focused on goal setting and maintaining motivation (Module 1), and 
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psychoeducation on the adaptive nature of emotions (Module 2), as well as a final relapse 
prevention module (Module 8).
Single Diagnosis Protocols (SDPs)—The SDPs included: Managing Social Anxiety: 
A Cognitive-Behavioral Therapy Approach – 2nd edition (MSA-II; Hope et al., 2006; Hope 
et al., 2000); Mastery of Your Anxiety and Panic – 4th edition (MAP-IV; Barlow & Craske, 
2007; Barlow & Craske, 2000); Mastery of Your Anxiety and Worry – 2nd edition (MAW-II; 
Zinbarg et al., 1994; 2006); and Treating Your OCD with Exposure and Response (Ritual) 
Prevention Therapy – 2nd edition (Foa & Kozak, 2004; Kozak & Foa, 1997; Foa et al., 
2008). Consistent with recommendations by the SDP treatment developers, patients with a 
principal diagnosis of SOC, GAD, or OCD received 16 sessions of SDP or UP treatment and 
patients with a principal diagnosis of PD received 12 sessions of SDP or UP treatment. 
Treatment sessions were approximately 50-60 minutes with the exception of 80-90 minutes 
for patients with a principal diagnosis of OCD.
Study therapists administered both the UP and SDP treatments as part of the trial. Therapists 
were doctoral students in clinical psychology, postdoctoral fellows, and licensed clinical 
psychologists with training and certification in the treatment protocols utilized (Barlow et 
al., 2000). Twenty percent of treatment sessions were randomly selected and rated for 
adherence and competence by raters associated with the development of the specific 
treatments. Treatment fidelity scores were good to excellent (mean: UP = 4.44; SDPs = 4.09 
out of 5).
Results
Analyses were conducted in SPSS 20.0. Item-level imputation, in which the mean of a 
participant’s responses was substituted for the missing value, was used when 30% or fewer 
of the items on a given scale were unanswered (Ake, 2005; Fox-Wasylyshyn & El-Masri, 
2005; Roth et al., 1999). Listwise deletion was used when more than 30% of the items were 
missing. The data were normally distributed and thus parametric statistics were used.
Associations with Anger at Baseline
Chi-square tests indicated that there were no significant differences between the three study 
conditions (UP, SDP, WLC) on the following demographic variables: gender (χ2 (2) = 1.95, 
p = .377), race (χ2 (2) = 5.30, p = .258), ethnicity (χ2 (2) = .89, p = .64), and principal 
diagnosis (χ2 (2) = 2.01, p = .734). A one-way ANOVA yielded no differences between 
conditions with regard to patients’ age (F(2) = 1.50, p = .238) or principal diagnosis CSR 
(F(2) = 1.34, p = .99).
The descriptive statistics for all measures can be seen in Table 1. Overall, the average level 
of anger in the study sample (M = 11.23, SD = 4.03) was within one standard deviation of 
that observed in the mixed inpatient/outpatient validation sample (M = 14.4, SD = 4.8; 
Watson & Clark, 1999). Chi-square analysis revealed no significant difference in anger 
based on gender (χ2 (12) = 10.31, p = .589). Differences in level of anger based on race and 
ethnicity could not be examined due to a lack of power, as only two patients identified as 
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Hispanic and/or non-Caucasian. A Pearson correlation showed no significant relationship 
between age and anger (r(35) = .22, p = .198).
Correlations were also used to examine the associations between anger and symptom 
severity. As seen in Table 1, and consistent with our hypotheses, higher levels of anger were 
significantly associated with greater overall depression and anxiety severity, greater severity 
of the principal diagnosis, and higher levels of neuroticism at baseline.
Relationship between Treatment Response and Anger
For all remaining analyses data were used only from those patients who received and 
completed active treatment (UP (N = 12) or SDP (N = 6) conditions). Differential attrition 
was characteristic of the full sample (see Barlow et al., 2017). As we have already 
established relationships between baseline anger and symptom severity, and with the 
knowledge that symptom severity may account for some of the variance in predicting 
response to treatment, we controlled for baseline symptom severity using a patient’s baseline 
CSR score for their primary diagnosis in the following logistic regression analyses. To aid in 
interpretation, we standardized the anger variable (M = 0, SD = 1). When predicting 
responder status (defined as having a subclinical CSR rating for the primary diagnosis), 
controlling for baseline severity, a test of the full model against an intercept-only model was 
statistically significant indicating that the predictors (baseline symptom severity and anger) 
as a set reliably distinguished between patients who did and did not respond to treatment (χ2 
(1) = 5.58, p = .018). The Wald criterion demonstrated that anger significantly predicted the 
likelihood of responding to treatment above and beyond the variance predicted by baseline 
symptom severity (p = .042). Odds ratios indicated that when patients presented to treatment 
with one standard deviation above the mean on anger, their likelihood of responding was 
17% lower (OR = .17, 95% CI [0.03, 0.94]).
Change in Anger During Treatment
An independent samples T-test indicated that there was not a significant difference in anger 
level between the UP and SDP conditions at baseline (t(16) = −.48, p = .635). Additionally, 
the average anger level in each condition (Table 2) was within one standard deviation of that 
observed in the validation sample, using inpatients and outpatients, suggesting that the level 
of anger reported in this sample is characteristic of that observed in patients with 
heterogeneous psychological disorders (Watson & Clark, 1994). Contrary to our predictions, 
a paired samples T-test indicated that anger did not significantly change over the course of 
treatment (t(17) = −.35, p = .733) in the overall sample of patients who received active 
treatment (UP and SDP combined).
Next, one-way ANCOVA was conducted to compare post-treatment anger levels between the 
two treatment conditions while controlling for baseline anger. Levene’s test indicated equal 
variances between the two treatment groups (F(1,16) = .05, p = .82). Results of the 
ANCOVA suggested that there was a significant difference in post-treatment anger scores 
between the two treatments (F(1, 17) = 4.62, p = .048). A comparison of the estimated 
marginal means showed that patients in the UP had lower anger scores at post-treatment (M 
= 10.09, SE = .55) than those in the SDPs (M = 12.15, SE = .78).
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As seen in Table 2, anger level decreased slightly, on average, in the UP condition and 
increased in the SDP condition. This change appeared to be independent of changes in 
symptom severity as a chi-square test indicated that there were a similar number of 
responders in the UP and SDP conditions (X2(1) = .62, p = .42). To explore the magnitude of 
the changes in anger, effect sizes, (Standardized Mean Gain, ESsg) were calculated from 
pre-post treatment within each condition. This effect size was chosen because it includes a 
correction for repeated measurements (Laken, 2013). Effect sizes were interpreted 
conservatively with 0.2, 0.5, and 0.8 representing small, medium, and large effects 
respectively (Cohen, 1988). Within the UP condition, there was a small, non-significant, 
decrease in anger (ESsg = −0.14, SEsg = 0.15, 95% CI [−0.43 : 0.16]). In the SDP condition, 
this effect size indicated a moderate, non-significant increase in anger (ESsg = 0.42, SEsg = 
0.23, 95% CI [−0.04 : 0.87]). This result was unexpected, as one might predict that treatment 
would be associated with a decrease in anger in both conditions. However, an examination of 
each individual participant’s scores showed that 5 out of the 6 patients in the SDP condition 
reported an increase in anger over the course of treatment. In the UP condition, five out of 
12 patients showed a decrease (41.7%), 5 showed no change, and 2 showed an increase in 
anger over the course of treatment.
Discussion
The overarching goal of the present study was to conduct an initial evaluation examining 
patterns of change in anger during CBT treatments for emotional disorders. First, we sought 
to replicate existing literature suggesting that anger is associated with greater emotional 
disorder symptom severity and predicts poorer treatment response. Consistent with our 
hypotheses, anger was significantly related to depression and anxiety symptoms, severity of 
the principal diagnosis, and neuroticism at baseline. Given that the level of anger in this 
sample was in line with the mean of a clinical sample, this result highlights the strong effects 
anger can have for patients, even when within the average range. Additionally, collapsed 
across active treatment conditions, anger at baseline was also associated with poorer 
prognosis at post-treatment. Given that anger is a potentially modifiable pre-treatment 
characteristic that predicts poorer outcomes, these results suggest that it may be important 
for clinicians to assess the propensity to experience this emotion and, if elevated, address it 
in treatment.
An additional goal of the present study was to take an initial look at the extent to which 
anger levels decrease during a course of CBT focused on anxiety disorders. Collapsed across 
conditions, anger did not change significantly from pre- to post-treatment. Additionally, 
while anger appeared to decrease in the UP condition and increase in the SDP condition, 
these results were non-significant. However, there was a significant difference in anger 
between the two conditions at post-treatment such that patients in the UP condition had 
lower anger scores than those who received SDPs. Interestingly, the UP and SDP conditions 
had a comparable number of treatment responders in terms of anxiety symptom severity. 
Taken together, these findings suggest that anger may respond differently to distinct 
interventions and lends preliminary support to the notion that an emotion-focused, 
transdiagnostic approach to emotional disorders may be an effective and efficient way to 
address co-occurring anger when it is present. However, due to the small sample size, these 
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results should be interpreted with caution and require replication in addition to further 
exploration.
These findings have the potential to contribute to the field’s approach to treating 
dysregulated anger, particularly in the context of emotional disorders. Extant treatments that 
target this emotion have primarily been evaluated in the context of individuals for whom 
anger is the primary problem (e.g., inmates, spousal abusers, perpetrators of road rage). 
Unfortunately, meta-analytic results suggest that although anger-focused CBT may indeed 
address anger, it has limited impact on anxiety and depression (DiGiuseppe & Tafrate, 
2003). This may be problematic given the high prevalence of anger in the context of 
emotional disorders (see: Cassiello-Robbins & Barlow, 2016), described in detail above. In 
contrast, the UP addresses the range of emotional disorders by targeting interfering 
emotional experiences more broadly, rather than concentrating on the circumscribed 
emotions relevant for a single presentation (e.g., focusing on fear in panic disorder). 
Transdiagnostic treatments like the UP are in line with the framework provided by the 
National Institute of Mental Health’s Research Domain Criteria (RDoC), which supports the 
use of psychological treatments that target core deficits appearing across a range of disorders 
(Insel et al., 2010). The UP is specifically in line with this initiative because the model of 
emotional disorders on which it intervenes is derived from converging cognitive and 
affective neuroscience, behavioral, and physiological, and genetic data that support the 
presence of the core vulnerabilities targeted by this treatment (i.e., aversive, avoidant 
reactions to strong emotions; Wilamowska et al., 2010). This approach allows for the 
flexible application of a single set of skills that are relevant to all dysregulated emotional 
experiences, thus making it useful for targeting dyregulated anger when clinically indicated.
Specifically, the UP targets aversive, avoidant reactions to emotions that paradoxically 
increase their frequency and intensity in the long-term. While this model has primarily been 
evaluated in the context of anxiety, fear, and depression, there is theoretical evidence to 
suggest that it may also be appropriate for dysregulated anger (see: Cassiello-Robbins & 
Barlow, 2016). In fact, one purported function of anger itself is to avoid the experience of 
more vulnerable emotions like anxiety and depression (Cassiello-Robbins et al., in 
preparation), underscoring its prevalence in the context of emotional disorders. As such, it is 
crucial that treatment for emotional disorders be relevant for the full range of emotional 
experiences. The fact that patients in the UP condition had lower anger scores at post-
treatment than those who received SDPs provides preliminary support for the idea that the 
UP is well poised to target an array of emotions.
The findings of the present study must be interpreted in the context of its limitations. First, 
given that anger was not assessed for the full duration of the trial, we were left with a small 
sample that completed the anger measure. Additionally, recruitment for this trial was 
stratified to enroll equal numbers of the four principal diagnoses; to accomplish this goal, we 
were heavily recruiting individuals with PD/A and OCD in the latter half of the trial, after 
the addition of our anger measure. As a result, most patients in the present study received a 
principal diagnosis of PD/A and OCD; thus, it is possible that our findings will not 
generalize to other emotional disorders. Additionally, our measure of anger, the PANAS-X, 
can be administered in reference to several windows of time (e.g., past week, past month, 
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generally). The present study asked participants to endorse the degree to which they 
generally experience anger, which may have limited our measurement precision with regard 
to pre- to post-treatment changes in this emotion. Finally, the PANAS-X assessed anger as a 
normally distributed trait. A review of anger assessments (Eckhardt, Norlander, & 
Deffenbacher, 2004) noted the importance of clarity as to whether or not anger is being 
measured as a pathological condition (i.e., the extent to which it is persistently distressing 
and interfering). Future research should consider using assessments that examine the extent 
to which an individual’s anger is pathological. In particular, standardized measures of trait 
anger or anger pathology are needed to replicate the association of dysregulated anger with 
symptom severity.
Despite these limitations, the current study adds to the existing literature on the role of anger 
in the treatment of emotional disorders. Our findings support the accumulating evidence that 
anger is associated with greater emotional disorder symptom severity and poorer prognosis. 
Further, our work suggests that dysregulated anger may not be appropriately addressed in 
the context of standard CBT protocols focused on discrete DSM-5 diagnoses. In contrast, 
transdiagnostic, emotion-focused CBT approaches, such as the UP, appear to be associated 
with lower levels of anger at post-treatment. This may be due to the fact that within a 
transdiagnostic treatment framework, attention can be paid to any emotional experience 
(e.g., anxiety, depression, guilt, anger) that causes distress and impairment. Given that anger 
often occurs in the context of emotional disorders, flexible approaches in which the same 
skills are relevant for a range of emotional experiences are paramount. The results of this 
exploratory work suggest that additional research examining the utility of transdiagnostic 
treatments for addressing dysregulated anger in the context of emotional disorders may be 
beneficial.
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Table 2
Means and Standard Deviation of Anger Scores by Group at Baseline and Post-Treatment.
Group Baseline Mean(SD) Post-Treatment Mean(SD)
UP (n = 12) 10.33(3.65) 9.83(3.74)
SDP (n = 6) 11.17(2.93) 12.67(3.67)
Note. UP = Unified Protocol treatment group, SDP = single diagnosis protocol treatment group
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